Guest Post: Nine Mandatory Licences Allow Greater Access To Medicines In Ecuador

Health 1

What is a mandatory licence? Mandatory licenses are a legal remedy within the intellectual property flexibilities provided by the World Trade Organization allowing a government to grant permission to third parties to produce a patented product or use a patented process without the consent of the patentee, in order to address a priority status for the country.

WHO: Fight Ebola Now, Solve Patent Issues Later

WHO Ebola Briefing - Sept 2014

The world and the global health community have been taken by surprise by the worst outbreak of Ebola so far. The World Health Organization today (5 September) said a vaccine could be available in November 2014 if proven safe. So far, according to the WHO, intellectual property issues have not acted as a barrier to accessing potential treatments and vaccines, and the focus for now is on emergency measures to find health solutions.

Biosimilar Medicines Need Strong Regulation, IP Crucial For Innovation, Pharma Says

Biosimilar medicines might prove to be a new reservoir for innovation for the pharmaceutical industry. However, the complexity of their manufacture needs a stringent regulatory framework, according to the industry.

WHO Raises Its Voice To Underline Health Effects Of Climate Change

The World Health Organization this week is holding its first conference on health and climate change. The major objective of the conference is to raise awareness on the impact of climate change on health, according to the WHO, which said it aims to strengthen its voice in the debate.

Market Failure, Not IP, The Issue In Ebola Treatment Shortage, WHO Says

Faced with the worst outbreak of Ebola since its discovery some 40 years ago, the world is scrambling for treatments. A World Health Organization-convened panel of experts has decided it is ethical to use experimental treatments. Why is there no treatment available even after 40 years? Market failure, not intellectual property rights, says the WHO.

World Drug Regulatory Authorities Meet In Brazil; Biosimilars In Focus

Drug regulatory authorities are meeting this week in Rio de Janeiro, Brazil to discuss global regulatory issues such as vaccine regulation, falsified products, and pharmacovigilance. A “pre-conference” focused on biosimilars, with civil society warning on barriers to access to those products.

Global Medical Students Call For Shift To Health Over Trade, R&D

Universities Allied for Essential Medicines is calling for new incentive models for research and development so that new treatments can be found for neglected tropical diseases to fight antibiotic resistance, and is asking that health issues supersede trade interests.

Compulsory Licences Needed For Affordable Hepatitis C Innovative Drug Regimens

Compulsory licences should be issued to roll out generic versions of innovative HCV drugs. Only generic competition can push down the extortionate prices of these lifesaving medicines, while placing equitable access and public interest before monopolistic pharma companies’ business strategies, Daniele Dionisio argues.

New Medicines Patent Pool-Gilead Agreement For New HIV Drug In 112 Countries

The Medicines Patent Pool today announced a new licensing agreement with Gilead Sciences for a new treatment still undergoing clinical trials. This agreement is expected to allow Chinese and Indian generic manufacturers to provide low-cost versions of the drug in 112 low-and middle-income countries.